Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Gene Ther. 2015 Jan 8;22(3):237–246. doi: 10.1038/gt.2014.113

Figure 5. Arming of FusOn-H3 with Her2-COL-sFasL can enhance and extend the therapeutic effect of the oncolytic virus in vivo.

Figure 5

HCT116 subcutaneous tumors were established in the right flank of NSG mice by subcutaneous injection of 2.5×106 cells. Once tumors reached the diameter of 5mm they were intratumorally injected (arrow) with PBS as a control, 1×105 pfu FusOn-H3, or 1×105 pfu FusOn-H3-Her2-COL-sFasL. Tumors were measured every 3 days with a caliper. Percent change in tumor volume was calculated by dividing the daily tumor volume by the tumor volume measurement at day 0. These measurements were then averaged (n=5 mice per group). *p<0.05; **p<0.001 on day 21 according to student’s T test. Error bars represent ±SEM.